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Purpose: Akathisia remains a common side effect especially from antipsychotic medication. 
If the condition is diagnosed the management options are limited.
Subjects/methodology: We tested a structured relaxation program on nine patients with a 
diagnosis of schizophrenia suffering from akathisia. All patients were rated on Barnes Akathisia 
Scale (BAS) before the relaxation program, immediately after and again one week later.
Results: The mean BAS score was before the relaxation 3.3 which reduced to 1.4 immediately 
after to finally 1.0 a week later. A Wilcoxon signed ranks test revealed a significant reduction in 
BAS score from baseline to endpoint (P = 0.026; Z = -2.232) and a highly significant reduction 
from baseline to follow-up (P = 0.008; Z = -2.636).
Discussion: Although the study has a number of limitations the relaxation program appears 
to be a promising alternative to traditional treatment of akathisia. The patients appreciated the 
relaxation session but none of them managed to carry it out on their own without professional 
encouragement. The findings in this case series warrant further investigation with larger num-
bers of patients.
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Background
Akathisia (inability to sit still) is a movement disorder characterized by objective 
movements and restlessness and/or distress, which is common among patients under-
going treatment with psychotropic drugs. It is generally agreed that the syndrome of 
akathisia comprises both an objective and a subjective component.1 Although one of 
the main motivating factors for the development of second generation antipsychotics 
was to reduce the incidence and severity of treatment-emergent akathisia and other 
extrapyramidal side effects, these remain problematic and not uncommon:2 furthermore, 
akathisia can also be associated with antidepressant treatment.3
Although often extremely upsetting, the widely held view of an association between 
akathisia and suicidal behavior has not been proven in larger methodologically sound 
studies,4 and is mainly based on case reports. It is nevertheless a distressing problem 
that can reduce quality of life and may impede treatment compliance in some patients 
undergoing pharmacological treatment. In an attempt to make sense of the condition 
some patients develop a dysfunctional interpretation of the stressful symptoms.5
There is no general agreement on how to diagnose akathisia, and this has   hampered 
both research and clinical practice.6 If akathisia is recognized, current treatment 
options include reducing the daily dosage or withdrawal of the implicated medication, Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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or the addition of other medications. The most widely used 
  pharmacological interventions include anticholinergic drugs, 
beta-blockers, and benzodiazepines, but the evidence base 
to support these interventions is limited and treatment may 
entail risks such as development of hypotension, tolerance, 
and dependence.7 In fact the only small, randomized con-
trolled trial on biperiden showed no difference compared to 
saline water in the treatment of akathisia.8 Some of the most 
important differential diagnoses of akathisia are the presence 
of agitation and anxiety symptoms, and these can be helped 
significantly with structured relaxation programs.9   However 
to our knowledge a relaxation approach has not been exam-
ined in patients experiencing akathisia associated with 
antipsychotic drugs, therefore the aim of this short report is 
to investigate whether a relaxation approach would reduce 
akathisia in patients suffering from this syndrome.
Case series
Nine patients with a primary diagnosis of schizophrenia and 
currently experiencing distressing akathisia (measured on the 
Barnes Akathisia Scale [BAS]) were invited to participate in a 
structured relaxation program, lasting 12 minutes and consist-
ing of breathing (four exercises) and tension-relaxation (six 
exercises). The patients were selected specifically because they 
suffered from akathisia – all participants were receiving, or had 
recently received, pharmacological interventions for akathisia 
such as benzodiazepines, beta blockers, or procyclidine (see 
Table 1) leading to an unsatisfactorily response. However, the 
responsible clinicians had been reluctant to lower the dose of 
antipsychotic medication due to fears of deterioration of psy-
chotic symptoms. Each exercise lasted just over one minute. 
No patient declined the offer of this intervention. The program 
was directed by TL and FT. One patient (number 9) underwent 
a repeat of the relaxation program with TL during the week 
before the final follow-up assessment.
Results
All patients were rated (by LKH) using the BAS,10 before the 
intervention (baseline, BAS median, 3), after the relaxation 
session (endpoint, BAS median 2), and again one week later 
(follow-up BAS median, 2). The short follow-up period was 
decided on to minimize the risk of changes to the medication 
Table 1 Demographic and clinical features, and effects of intervention
Patient Group or  
individual  
intervention
Gender Age Psychotropic or other  
medication
Baseline  
BAS score
Endpoint  
BAS score
Follow-up 
BAS score
1 Group M 46 Flupentixol 9 mg  
Amisulpride 400 mg  
Procyclidine 10 mg
4 1 1
2 Group  M  22 Olanzapine 20 mg 4 0 1
3 Group  M 29  Olanzapine 30 mg  
Levopromazine 50 mg  
Temesta 3 mg
4 1 1
4 Group  M 59 Pipamperone 120 mg  
Olanzapine 7.5 mg  
risperdone consta 50 mg  
Procyclidine 10 mg  
Tranxene 30 mg
2 0 0
5 Group  M 47 Quetiapine 600 mg 3 3 2
6 Group  M 29 Prothipendyl 40 mg  
Olanzapine 20 mg  
risperdone 4 mg  
Procyclidine 15 mg
3 0 0
7 Group  F 31 risperdone consta 37.5 mg  
Aripiprazole 15 mg  
Alprazolam 1 mg
3 3 3
8 Group  M 31 Amisulpride 800 mg  
Aripiprazole 15 mg
3 1 0
9 Individual  F 37 Clozapine 600 mg  
Pipamperone 120 mg  
Olanazapine 7.5 mg  
Levomepromazine 25 mg  
Biperdin hydrochloride 2 mg 
4 4 1
Abbreviation: BAs, Barnes Akathisia scale.Neuropsychiatric Disease and Treatment
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regime that could have made the patients unsuitable for the 
study. All patients were given a written version of the program 
  following the sessions, but according to self-reports, none 
managed to undertake the program on their own in the week 
before follow-up. There were no changes to   medication 
regimes in any patient, during the study period.
A Wilcoxon signed rank test showed a significant reduc-
tion in BAS score from baseline to endpoint (P = 0.026, 
Z = -2.232) and a highly significant reduction from baseline 
to follow-up (P = 0.008; Z = -2.636). No significant differ-
ence was however found between endpoint and follow-up 
(P = 0.257; Z = -1.134). The calculations were carried out 
on SPSS (version 16.0; SPSS lnc., Chicago, IL).
Discussion
These findings are promising, although it is possible that the 
benefits were at least partly due to factors such as increased 
attention and greater contact with other patients and staff. 
Other limitations in this report include the small sample size, 
preliminary pilot nature of the data, use of a potentially biased 
(LKH) rater, and the uneven completion of the relaxation 
program in some patients. Although the number of patients 
was limited, all but one patient appeared to have benefited 
from the relaxation program. The approach was received 
enthusiastically by the participating patients, but no patient 
managed to perform the program on their own without pro-
fessional intervention. No detrimental effect was seen in the 
mental state of any patient.
The structured relaxation program appeared to be well 
accepted and to be associated with a notable reduction in the 
severity of symptoms of akathisia in this group of patients 
with chronic schizophrenia, treated with antipsychotic drugs. 
The pathophysiology underlying akathisia is not fully under-
stood, and current treatment approaches are less than ideal. It 
is important to develop evidence-based alternatives to current 
interventions that are feasible in routine clinical practice. The 
mechanism underlying the reduction in symptoms of akath-
isia with the structured relaxation program is uncertain but 
biofeedback methods may be at least partly responsible for 
the beneficial effect. Biofeedback is a process that enables 
a person to change physiological activity (eg, heart rate, 
muscle activity). It is conceivable that the relaxation program 
improved the patients’ ability to minimize the restlessness 
characteristic of akathisia. The sustained effect at 1-week 
follow-up is intriguing and warrants further study, possibly 
comparing structured relaxation with current pharmaco-
logical treatment options, such as use of beta-blockers or 
benzodiazepines in an open label clinical trial.
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